We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Isorhapontigenin improves the sensitivity of non-small cell lung cancer cells to gefitinib by inactivation of the SP1/EGFR pathway.
- Authors
Xingshu Wu; Zhixiang Su; Xiaoping Ren
- Abstract
Non-small cell lung cancer (NSCLC) remains one of the most common cancers in the world. The aim of this study was to explore the therapeutic potential of isorhapontigenin (ISO) to overcome gefitinib resistance in NSCLC cells. Cell viability was higher in gefitinib-resistance A549 (A549/R) cells than that in A549 cells in response to gefitinib. Combination of gefitinib and ISO enhanced the reduction in cell viability and cell colony number induced by gefitinib or ISO alone. The number of apoptotic cells was increased in gefitinib and ISO combination group compared with A549/R cells treated with gefitinib or ISO alone. Combination of gefitinib and ISO inhibited the repairment of DNA damage in A549/R cells and repressed the activation of SP1/EGFR signaling pathway. In summary, data of this study proved that ISO enhanced the sensitivity to gefitinib through inactivation of SP1/EGFR signaling pathway in gefitinib-resistant NSCLC cells.
- Subjects
NON-small-cell lung carcinoma; GEFITINIB; CANCER cells
- Publication
ScienceAsia, 2022, Vol 48, Issue 5, p545
- ISSN
1513-1874
- Publication type
Article
- DOI
10.2306/scienceasia1513-1874.2022.082